Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
about
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsAACR Cancer Progress Report 2014Current global status & impact of human papillomavirus vaccination: Implications for IndiaRationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaCross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.How advances in immunology provide insight into improving vaccine efficacy.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Why HIV virions have low numbers of envelope spikes: implications for vaccine development.Alternative dosage schedules with HPV virus-like particle vaccines.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsHPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Outness, Stigma, and Primary Health Care Utilization among Rural LGBT Populations.Bacterial superglue enables easy development of efficient virus-like particle based vaccines.A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionImmunoprevention of human papillomavirus-associated malignanciesThe case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.Raising expectations for subunit vaccinePreclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® VaccineEpitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform.A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.Using discrete choice modeling to evaluate the preferences and willingness to pay for leptospirosis vaccineA comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.HPV vaccine: One, two, or three doses for cervical cancer prevention?Impact of an Electronic Health Record (EHR) Reminder on Human Papillomavirus (HPV) Vaccine Initiation and Timely CompletionNatural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized studyImmunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls
P2860
Q27013018-4B9900B9-4213-446F-B71C-1388713FD8E7Q27346723-E0C60567-6683-404E-99A5-2C6D81107EE4Q28079776-AECD4E3E-C4DC-493D-9D23-DC0DDC7DA931Q30300329-3BB6AFE8-2E7C-4218-B89A-7A64B2796C09Q30353668-DA7021C0-39C2-4C87-96F1-AE879039BED1Q30384943-89F1FC77-6CE6-4C8E-9DB5-B38097FA94F4Q30970916-F622A426-E561-4F26-94D0-05BA8E4EE19EQ30980654-5ABA3413-214D-4EB3-A398-F56F7ED164D8Q33723312-38AFD4AA-9D2B-47D3-B770-C4DF7833CBABQ33896995-D8C0B87D-DE41-4517-9D41-21CD0FF7919EQ33953881-8C04EC5A-1EC4-40B5-9F70-F68550EACD6FQ34016070-046264E2-F8DE-447E-83C0-22142322D156Q34102466-4FF402C3-E76D-489A-9B77-3DD060B232F2Q34199560-2CA713AB-7F29-45EE-96CA-CC1F72C95129Q34492140-7B0FD54A-EBFF-43EF-9498-CA829A21DC3FQ34507291-44C60E9E-FD2D-42A6-BBE6-3751BADA3C10Q34507411-3DC2DF96-721D-4C20-A02A-DD68802C3736Q34523734-FFACAF21-82B6-4252-A8FE-F83D3061181BQ34970731-5961B3AA-7E90-41AA-9384-0779CD7F3EDAQ35044376-63F676FE-1BBF-4202-9B7D-11210743DF2AQ35078557-56D42357-E6BE-4AD0-B061-04B2BE281B40Q35095954-FC8C0A42-9094-4A66-9ED9-10AA5614A6B6Q35227478-782C25C6-AFD2-4D59-BB93-C0393FE54C47Q35452705-D8930849-7B77-4ED8-9440-76FD76EF51ECQ35744303-5EF091A6-738C-4700-BCB3-D51B8292A277Q35818648-8E2F7531-0C04-4214-9366-33CACAC5A80FQ35827034-60C87D30-DB95-4476-B623-83B1FFA3416DQ35850159-0EC0F84C-B37F-4413-B316-3669C394097EQ35886468-3708A12F-CBCD-47CD-B0DC-3DB82F18A979Q35887386-A876DABD-556B-4513-91B9-6FC99B4D365BQ35887709-47056167-D6A5-49A7-AAAF-235DA32AB85CQ36457994-7EEE070D-FB0D-4575-B786-934FA7AB4AE4Q36603668-E1435C21-58F3-49AF-BAA9-3D74C16D5BC8Q36745242-1806BBF9-9532-432A-9409-64E1E8E31F4EQ36957800-47C9FB4C-54D6-4DDE-BAC9-08193F572E42Q36977720-19C14F14-E43A-406D-8729-F2E33306B83FQ36978399-A63FD770-9505-4A77-947E-3EC59D460F58Q37114360-1DA8B53A-1A71-4E25-8FBC-956BB77E0ADCQ37118381-013CC039-2480-4FCB-8EBC-B2D9B51B8FFBQ37135276-9AF731A7-0377-42BC-B2F5-1404C0A4A933
P2860
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@en
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@nl
type
label
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@en
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@nl
prefLabel
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@en
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@nl
P2093
P1476
Durable antibody responses fol ...... the Costa Rica Vaccine Trial.
@en
P2093
Aimee Kreimer
Allan Hildesheim
Ana C Rodriguez
Carolina Porras
Douglas R Lowy
Gloriana Shelton
John T Schiller
Leen-Jan van Doorn
Ligia A Pinto
P304
P356
10.1158/1940-6207.CAPR-13-0203
P577
2013-11-01T00:00:00Z